Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22802070 | 0.86 | LPL (0.33) | P2RX7MAPK1 | |
| SCHEMBL17397880 | 0.82 | ERN1 (0.40) | P2RX7MAPK1 | |
| SCHEMBL20861592 | 0.82 | ERN1 (0.40) | P2RX7MAPK1 | |
| SCHEMBL17397902 | 0.78 | LMNA (0.47) | P2RX7MAPK1 | |
| SCHEMBL17397866 | 0.78 | LMNA (0.37) | P2RX7MAPK1 | |
| SCHEMBL28476218 | 0.75 | ALDH1A1 (0.37) | — | |
| SCHEMBL134815 | 0.73 | SRC (0.38) | — | |
| SCHEMBL13111262 | 0.73 | ALDH1A1 (0.37) | — | |
| SCHEMBL22712438 | 0.73 | HIF1A (0.34) | MAPK1 | |
| SCHEMBL20936654 | 0.72 | CA1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-12-05 | — | — | US | disclosed |
| WO-2024172631-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | 주식회사 카나프테라퓨틱스 | 2024-08-22 | — | — | WO | disclosed |
| EP-4389738-A1 | SOS1 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | SOS1, RAC1, SOS2 | P2RX7 3494/4885MAPK1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.